Abstract. Naturally acquired antibody reactivity to two major Plasmodium vivax vaccine candidates was investigated in 294 donors from three malaria-endemic communities of Rondônia state, Brazil. Antibody recognition of recombinantly expressed antigens covering five different regions of P. vivax reticulocyte binding protein 1 (PvRBP1) and region II of P. vivax Duffy binding protein (PvDBP-RII) were compared. Positive IgG responses to these antigens were significantly related to the level of malaria exposure in terms of past infections and years of residence in the endemic area when corrected for age. The highest prevalence of anti-PvRBP1 total IgG antibodies corresponded to the amino acid regions denoted PvRBP1 
INTRODUCTION
Plasmodium vivax accounts for an estimated 80 million cases occurring throughout most of Asia, Oceania, southeastern Europe, Central and South America, and parts of Africa. 1 Despite its wide geographic distribution, P. vivax has long been overshadowed by the burden caused by Plasmodium falciparum, which causes more than 1 million deaths per year in sub-Saharan Africa alone. 2 The disproportionate morbidity and mortality figures are a major reason why research on P. vivax has lagged far behind that of P. falciparum. As of now, more than 23 different P. falciparum vaccines are currently undergoing clinical trials compared with only two P. vivax vaccine trials. 3, 4 However, the phylogenetic and antigenic disparity between the two species implies that effective falciparum vaccines will not be cross-protective against vivax infections. In light of rising drug resistance in P. vivax and its increasing prevalence, it is imperative to advance the development of more P. vivax antigens as vaccine candidates. 5 Malaria blood-stage vaccines aim to disrupt interactions between receptors on Plasmodium merozoites and their erythrocytic ligands by eliciting inhibitory antibodies that target the parasitic receptors. One such target unique to P. vivax is the Duffy binding protein (PvDBP), 6, 7 a Type I integral membrane protein whose homologues in Plasmodium knowlesi and P. falciparum have been localized by immunoelectron microscopy to the micronemes of merozoites. 8, 9 PvDBP mediates the invasion of erythrocytes via interactions with its erythrocytic ligand, the Duffy antigen receptor for chemokines (DARC). 6 Invasion of human erythrocytes by P. vivax requires this interaction, as individuals deficient in DARC are not susceptible to infection. 10 The PvDBP erythrocyte binding domain, designated region II (PvDBP-RII), has been mapped to an ∼350 amino acid cysteine-rich region near the amino-terminus. 11 Region II has significantly higher diversity than the rest of the PvDBP and appears to be under strong selective pressure. 12 In addition, naturally occurring antibodies from humans exposed to malaria have been demonstrated to inhibit the in vitro binding of erythrocytes to region II, suggesting an antiparasitic role of the naturally acquired immune response. 13 The functional and immunologic significance of PvDBP-RII has supported its candidacy as a vaccine.
Two other P. vivax candidate antigens are the reticulocyte binding proteins (PvRBP1 and PvRBP2), which were identified based on their ability to preferentially adhere to reticulocyte-enriched populations of erythrocytes. 14, 15 Evidence suggests that the two PvRBPs form a complex at the apical pole of the merozoite and confer the reticulocyte-specificity of P. vivax blood-stage infections. 14, 16 PvRBP1 and PvRBP2 are both Type I integral membrane proteins of approximately 330 kDa, each consisting of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. Homologues with similar structures have subsequently been identified and characterized in P. falciparum. [17] [18] [19] Global diversity analysis of these genes has revealed a cluster of nonsynonymous polymorphisms within the first 750 amino acids of the PvRBP1 extracellular domain, 20 suggesting that this region may be the target of immune selection. Despite evidence that the PvRBPs play an important role during the P. vivax invasion of reticulocytes, the immunogenicity of these proteins has yet to be studied. Furthermore, evidence for naturally occurring antibodies reactive against PvRBPs has not been demonstrated in a malaria-exposed population. Given the large size of PvRBP1, the identification of functional subdomains and protective B-cell epitopes would prove valuable in the development of a PvRBP1 subunit vaccine.
Toward these goals, we have screened plasma samples from a cross section of three epidemiologically distinct communities in the Brazilian Amazon state of Rondônia for the presence of IgG antibodies against five recombinant fragments spanning the length of the PvRBP1 extracellular domain. For comparative purposes, we also tested the same plasma samples for antibodies against a recombinant, refolded PvDBP-RII. 21 We used malaria infection and exposure histories obtained from individual donors to assess the relationship between exposure and naturally acquired antibody responses to PvRBP1 and PvDBP-RII. Previous seroepidemiological studies in hyperendemic areas of Africa have shown cytophilic antibody subclasses IgG1 and IgG3 to be associated with acquired protection to falciparum malaria. 22 Furthermore, in vitro studies have demonstrated that cytophilic antibodies mediate their antiparasitic effect by engaging with Fc␥ receptors on monocytes. 23, 24 We therefore evaluated the IgG subclass reactivities in positive responders and determined the subclass distribution for both PvRBP1 and PvDBP-RII. This study provides the first insights into immune responses made against these two blood-stage vaccine candidates upon natural exposure to P. vivax.
MATERIALS AND METHODS
Study site and subjects. Cohort studies were conducted in populations living in three communities in the malaria endemic region of Rondônia state, Brazil, where vivax malaria accounts for more than 70% of all malaria cases in the past 3 years (Brazilian Ministry of Health, 2004, unpublished data). Samples and survey data were collected during the dry months of June and July of 2001, coinciding with the period of increased malaria transmission. The two communities of Colina and Ribeirinha have been described previously. [25] [26] [27] Briefly, Colina consists primarily of transmigrants from nonendemic areas of Brazil who have lived in the region for 10 years or more. They reside in rural settlements alongside unpaved roads that traverse the transnational highway BR-364 approximately 50-100 km southeast of the capital, Porto Velho. Ribeirinha encompasses riverine communities along the banks of the Madeira River and its tributaries approximately 30-60 km northeast of the capital. Families in Ribeirinha have lived in the malaria-endemic region for more than 25 years, and many are native to the region. The third group lives in Buritis, a newly developed municipality situated approximately 300 km due south of the capital. Most individuals from this group consist of transmigrants who have resided in the endemic region for less than 10 years. The study population consisted of 87 donors from Colina, 177 donors from Ribeirinha, and 30 donors from Buritis. Age ranged from 9 years to 85 years, but most donors were between 20 to 40 years of age. Written informed consent was obtained from all adult donors or from parents of donors in the case of minors. The study was reviewed and approved by the Fundação Oswaldo Cruz Ethical Committee.
Epidemiologic survey. Donors giving informed consent answered questions from an epidemiologic survey. Questions on the survey related to demographics, time of residence in the endemic area, personal and family histories of malaria, use of malaria prophylaxis, presence of malaria symptoms, and personal knowledge of malaria. Survey data was entered into a database created with Epi Info 2002 (Centers for Disease Control and Prevention, Atlanta, GA). Demographic and epidemiologic data are summarized in Table 1 .
Collection of human blood samples and malaria diagnosis. Intravenous blood was collected in sodium heparin Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ). Cellular components were separated from plasma by centrifugation, and aliquots of plasma were frozen and stored at −20°C until use for antibody analysis. Thin and thick blood smears of all donors were examined for malaria parasites. The numbers of donors positive for P. vivax and P. falciparum at the time of phlebotomy are listed in Table 1 . Parasitemia for smearpositive donors was determined by counting the number of parasites against a predetermined number of white blood cells in thick blood smears, and, from this, the number of parasites per l of blood was calculated. 28 Infected donors who were asymptomatic at the time of phlebotomy were followed up the next day to confirm absence of malaria symptoms. All smear-positive donors were subsequently treated for P. vivax or P. falciparum per the regimen recommended by the Brazilian Ministry of Health.
Protein expression and purification. Five overlapping fragments spanning the PvRBP1 extracellular domain and PvDBP-RII were expressed as recombinant proteins in Escherichia coli and subsequently purified as described below. The expression and purification of recombinant, refolded PvDBP-RII have been described previously. 21 In addition, thioredoxin, used as a control for nonspecific IgG reactivity, was expressed and purified from Escherichia coli BL21(DE3) (Novagen, Madison, WI) containing the plasmid pET32b (Novagen) using standard procedures suggested by the manufacturer. Recombinant proteins were used to detect the prevalence of antibodies in plasma samples by enzyme-linked immunosorbant assays (ELISA).
Five overlapping regions of Pvrbp1 spanning nucleotides 67 to 7832 of the coding sequence were amplified from P. vivax Belem strain genomic DNA using the Expand High Fidelity polymerase chain reaction (PCR) system (Roche, Indianapolis, IN). The regions (shown in Figure 1 ) were selected based on global diversity data 20 and protein stability index as determined by ExPASy ProtParam program. 29 The primers, cloning sites, and expression vectors used for each construct are listed in Table 2 . The PCR product PvRBP1 was cloned into pDONOR2.1 (Invitrogen, Carlsbad, CA) before subcloning into the expression vector pDEST17, yielding the recombinant plasmid PvRBP1 23- , Luria-Bertania media containing 100 g/mL ampicillin (LB-amp) was inoculated and cultured at 37°C until the optical density at 600 nm (OD 600 ) reached 0.6-0.8. Cells were induced to produce protein with 1 mM isopropyl-1-thio-␤-galactopyranoside (IPTG) for 3 hours at 37°C. The soluble 6-His recombinant proteins were purified with Ni-NTA agarose (Qiagen, Valencia, CA) per the manufacturer's instructions before gel filtration chromatography. Protein samples were loaded on a Sephacryl S-300 (Amersham Pharmacia Biotech, Piscataway, NJ) gel filtration column equilibrated with 20 mM Tris-HCl, pH 8.0, and eluted with 20 mM TrisHCl buffer, pH 8.0, containing 500 mM NaCl. Fractions from the major peak based on absorbance 280 were pooled, dialyzed overnight against phosphate-buffered saline, pH 7.4 (PBS; Cellgro, Herndon, VA), concentrated by ultrafiltration, and stored at −80°C.
The insoluble recombinant proteins PvRBP1 and PvRBP1 2038-2611 were isolated as inclusion bodies, reconstituted by step dialysis, and purified by gel filtration chromatography. Escherichia coli BL21(SI) containing plasmid PvRBP1 23-458 /pDEST17 was cultured in salt-free LB-amp at 37°C until an OD 600 of 0.8-1.0, and protein expression was induced with 0.3 M NaCl for 4 hours. For PvRBP1 2038-2611 , LB containing 50 g/mL kanamycin (LB-kan) was inoculated and grown at 37°C to an OD 600 of 0.8-1.0, and protein expression was induced with 1 mM IPTG for 4 hours. Bacteria pellets were harvested and resuspended in 50 mM Tris-HCl, pH 8.0 containing 25% (w/v) sucrose, 1 mM ethylenediaminetetraacetic acid (EDTA), and 10 mM dithiothreitol (DTT) before freezing at −80°C. The resuspension was thawed, and 1 mg/mL lysozyme, 5 mM MgCl 2 , 2 mg/mL DNase, 1% Triton-X 100, and 10 mM DTT were added. Cells were lysed by sonication and pelleted by centrifugation before resuspension in 50 mM Tris-HCl, pH 8.0, containing 0.5% Triton X-100, 100 mM NaCl, 1 mM EDTA, 0.1% azide, and 1 mM DTT. Sonication, centrifugation, and resuspension steps were repeated four more times, with Triton X-100 excluded in the last wash. The washed pellets were dissolved in 25 mM 2-[Nmorpholino] ethane sulfonic acid, pH 6.0, containing 8 M urea, 10 mM EDTA, 0.1 mM DTT, and these inclusion bodies were stored at −80°C. PvRBP1 and PvRBP1 2038-2611 inclusion bodies were reconstituted by 1:2 dilution with 50 mM glycine, pH 8.0 containing 10% w/v sucrose, 1 mM EDTA, 1 mM reduced gluthathione, 0.1 mM oxidized glutathione, and 4 M urea and dialyzed for 24 hours at 4°C against a 50× volume of the same buffer. The dialysis buffer was exchanged with a 50x volume of 20 mM Tris-HCl, pH 8.0, containing 10% w/v sucrose, 1 mM EDTA, 0.1 mM reduced glutathione, 0.01 mM oxidized glutathione and dialyzed for 24 hours at 4°C. Samples were concentrated to an appropriate volume and further purified by gel filtration chromatography as described above. Purity and stability of all recombinant proteins were verified by SDS-PAGE ( Figure 2 ) and Western blot analysis using an anti-penta-His monoclonal antibody (mAb; Qiagen; supplemental Figure 1 ).
Measurement of antibody levels. Plasma samples from study participants were screened for total IgG reactivity against the five PvRBP1 constructs, PvDBP-RII, and purified thioredoxin using ELISA for total IgG antibodies. Maxisorp 96-well plates (Nunc, Rochester, NY) were coated with 200 ng of antigen overnight at 4°C in PBS, pH 7.4. Plates were washed four times with PBS-0.05% Tween 20 (PBS-T) and blocked with blocking buffer (PBS-T containing 5% skim milk) for 2 hours at 37°C. Plates were washed once and incubated for 1 hour at 22°C with plasma diluted 1:100 in blocking buffer. After washing four times, the plates were incubated for 1 hour at 22°C with peroxidase-conjugated goat anti-human IgG (␥ chain specific) (KPL, Gaithersburg, MD) diluted 1:3000 in blocking buffer. Plates were washed four times and incubated for 30 minutes at 22°C with 2, 2'-azinodi(3-ethylbenzthiazoline-6-sulfonate) substrate (ABTS, KPL) per the manufacturer's instructions. The ODs were measured at 405 nm, and the threshold for positivity was an OD value set at 3 SD above the mean OD of 30 residents of either the United States or Brazil who have never been exposed to malaria transmission. For the three thioredoxin fusion proteins, background antibody reactivity to thioredoxin was subtracted from raw ODs before further analysis. Average cutoffs were 0.607 (PvRBP1 For positive responders, end-point titers were determined using 1:2 serial dilutions starting at 1:100. The end points were determined as the highest titers in which the OD was greater than the threshold for positivity at a control plasma dilution of 1:100. An ELISA to detect the IgG subclasses of the anti-DBP and anti-RBP antibodies was also performed for positive responders. Plates were coated with antigen, blocked, and incubated with plasma diluted 1:100 as in the ELISA for total IgG. After washing, plates were incubated for 1 hour at 22°C with mouse mAbs to human IgG subclasses diluted in blocking buffer according to the manufacturer's specifications. The mAbs were from clones HP-6001 for IgG1, HP-6002 for IgG2, HP-6050 for IgG3, and HP-6023 for IgG4 (Sigma, St. Louis, MO) and have been used previously to characterize IgG subclass reactivity in the Ribeirinha population. After incubation, plates were washed and incubated for 1 hour at 22°C with peroxidase-labeled goat anti-mouse antibody (KPL) diluted 1:1,000 in blocking buffer. Plates were washed, incubated with ABTS, and the OD measured as described above. Subclass-specific prevalence for each antigen was determined from OD values using 3 SD above the appropriate mean OD of 24 nonexposed controls as the cutoff for positivity (Table 3 ). In addition, standard curves were prepared to enable conversion of OD values to concentration (g/mL) values, thus allowing for the comparison of different subclasses. Purified human IgG kappa myeloma proteins from each of the four subclasses (The Binding Site, San Diego, CA) were coated overnight at 4°C in PBS at 100 L per well onto 96-well plates in 1:2 serial dilutions from 2 4 g/mL to 2 −11 g/mL. After washing four times, plates were incubated with the appropriate human IgG subclass-specific mAb, washed four times, incubated with peroxidase-labeled goat anti-mouse antibody, washed a final four times, developed with ABTS, and measured as described above for subclass-specific ELISA. Subclass-specific OD values were converted to concentration values (g/mL) using sigmoidal curve-fit equations derived from subclass-specific standard curves (supplemental Figure 2) .
Statistical analysis. Differences in medians for the study population data were tested by non-parametric KruskalWallis test where appropriate. Normalizing transformations were performed on raw data before testing by one-way analysis of variance where appropriate. Differences in proportions were evaluated by 2 test. Relationships between years of residence in the endemic area and number of past malaria infections or months since last known malaria episode were assessed with Spearman's rank correlation. Multivariate logistic regression was used to assess the relationship between antigen-specific total IgG responses and the independent variables of gender, age, years of residence in the endemic area, number of past malaria episodes, and months since last known malaria infection. For comparison of IgG subclassspecific antibody responses, 2 test was used to evaluate differences in prevalence. Normalizing transformations were performed on subclass concentrations before one-way analysis of variance (for evaluating differences in subclass distri- 2 analyses were performed to determine if a statistically significant difference existed between the seroprevalence of the three populations for each antigen. The level of significance is indicated by *(P < 0.05), **(P < 0.01), and ***(P < 0.001). bution within responders or within controls for each antigen) or Student's t test (for evaluating subclass-specific differences between responders and controls for each antigen). Spearman's rank correlation coefficients were calculated to determine the relationships between IgG subclass levels and months since last known malaria episode. Analyses were done using Epi Info 2002 and Prism 3.0 (GraphPad Software, San Diego, CA).
RESULTS
Characteristics of Buritis, Colina, and Ribeirinha. Table 1 shows the characteristics of the three communities studied. Among our sample set, the communities differ significantly in gender ratio, with Colina donors being disproportionately male. Median age is similar between the three communities. The proportion of transmigrants is highest in Buritis (90%) and lowest in Ribeirinha (11%). The communities differ significantly in years of residence in the endemic area, number of past malaria episodes, months since last malaria episode, and proportion of patent malaria infections as listed. Data was stratified by gender to account for male bias among Colina residents.
Relationship between years of residence in the endemic area and malaria history. For this study, we used years of residence in the endemic area and number of past malaria episodes as reported by donors as indices of malaria exposure. Absence of recent symptomatic malaria infection, measured as the number of months since a donor's last known malaria episode, was used as a crude approximation of protection. The number of past malaria episodes did not correlate significantly with years of residence in the endemic area (Spearman r ‫ס‬ 0.086, P ‫ס‬ 0.14, N ‫ס‬ 294). Among donors with a positive history of malaria, years of residence in the endemic area correlated positively with the number of months since a donor's last malaria episode (Spearman r ‫ס‬ 0.29, P < 0.0001, N ‫ס‬ 258).
Anti-PvRBP1 and anti-PvDBP-RII seroprevalence in three communities of Rondônia. Naturally acquired antibody responses to PvDBP-RII have been shown to have high prevalence in regions of vivax endemicity. 13, [30] [31] [32] Thus, antiPvDBP-RII IgG reactivity was used in this study to estimate the rate of exposure to P. vivax. Anti-PvDBP-RII seroprevalence was 67% among all 294 donors and 43%, 70%, and 70% for Buritis, Colina, and Ribeirinha communities, respectively. In comparison, seroprevalence for any of the five PvRBP1 fragments was 66% among all donors and 57%, 58%, and 72% for Buritis, Colina, and Ribeirinha, respectively. Of these five PvRBP1 fragments, the highest frequencies of positive responses among all donors were for PvRBP1 431-748 (41%) and PvRBP1 733-1407 (47%). Total IgG reactivity to PvRBP1 and PvRBP1 431-748 differed significantly among the three communities ( 2 ‫ס‬ 10.08, P ‫ס‬ 0.0065 and 2 ‫ס‬ 17.20, P ‫ס‬ 0.0002, respectively), with increased prevalence to both in Colina and Ribeirinha. The results are summarized in Figure 3 . Although there was a trend for anti-PvRBP1 IgG antibodies to be more prevalent in males than females, this difference was not statistically significant. Multivariate logistic regression analysis of total IgG antibody reactivity according to gender, age, and indices of malaria exposure. The contributions of five independent variables related to malaria exposure to total IgG antibody responses against each of the six vivax recombinant proteins were determined using stepwise, multivariate logistic regression. The variables initially tested were gender, age, years of residence in the malaria endemic area, number of past malaria episodes, and months since last known malaria episode. The initial analysis showed that gender did not affect IgG antibody responses to any of the recombinant antigens and was subsequently removed from the final regression analysis ( Table 4 ). The analysis demonstrated that IgG responses to the recombinant antigens were generally age independent but exposure dependent, except for responses against PvRBP1 , which appeared independent of both age and exposure. Individuals living in the malaria-endemic area for more than 30 years were 3.3 to 4.6 times more likely to react to PvRBP1 431-748 , PvRBP 2038-20611 , and PvDBP-RII than the most recently migrated individuals. Donors who reported having greater than 15 malaria infections were 4.4 to 7 times more likely to respond to PvRBP1 431-748 , PvRBP1 733-1407 , PvRBP1 1392-2076 , PvRBP1 2038-2611 , and PvDBP-RII than selfreported malaria-naïve individuals. Donors who have had a recent malaria infection (within two months preceding sample collection) were significantly more likely to respond to PvRBP1 2038-2611 and PvDBP-RII than those who have been malaria-free within this same period.
Seroprevalence and malaria exposure. All 294 donors from Rondônia were stratified according to years of residence in the endemic area (< 11, 11-20, 21-30, and > 30 years) and number of past malaria episodes (0, 1-5, 6-15, and > 15 malaria infections). The prevalence of total IgG antibodies against each antigen was plotted for each group (Figure 4) . Seroprevalence generally increased with years of residence in the endemic area and number of past malaria episodes for all antigens. This trend of rising seroprevalence was similar among the five PvRBP1 antigens. However, the prevalence of anti-PvRBP1 antibody responses was shown to increase at a slower rate than that of anti-PvDBP-RII antibody responses. Many donors who reported never having malaria responded to PvDBP-RII (11 of 31), PvRBP1 (16 of 31), or either antigen (21 of 31).
IgG subclass distribution of anti-PvDBP-RII and antiPvRBP1 antibodies. We assessed the overall subclass distribution of the IgG antibody responses to each antigen using two different comparative analyses. Firstly, we determined subclass-specific prevalence of total IgG positive responders for each antigen using background-subtracted OD values and OD cutoffs determined from ODs of controls. Secondly, antigen-specific IgG1, IgG2, IgG3, and IgG4 concentrations for total IgG positive responders were determined from OD values using subclass-specific standard curves and the results compared with the concentrations of controls using parametric statistics. Both analyses are summarized in IgG subclass levels and months since last known malaria episode. Time (in months) since a donor's last known malaria episode was used as a crude approximation of the donor's level of protection from malaria. To assess if IgG subclass levels correlated with this approximation, we calculated Spearman's correlation coefficients between IgG subclass concentrations and months since last known malaria episode for each antigen. Only donors who were identified as positive responders to a particular antigen were included in the analyses for that antigen. Donors who either had detectable levels of parasitemia or reported themselves as malaria-naïve were excluded from analyses. Months since last known malaria episode positively correlated with IgG3 concentration for 
DISCUSSION
Naturally acquired antibody responses against PvRBP1, one of the proteins implicated in conferring reticulocyte specificity of P. vivax invasion of red blood cells, have not been studied to date. This study attempts to characterize the acquired antibody response to PvRBP1 and PvDBP in malaria-endemic populations of Rondônia state in the Brazilian Amazon. Malaria transmission in this area is low but continuous throughout the year, with sharp increases in malaria incidence during the dry months of June, July, and August. 33, 34 Distinct rural communities of Rondônia represent the various temporal cohorts of transmigrants who have settled in the region during the past 40 years as a result of government social programs. 35 The seroepidemiology of malaria infection in these communities has been studied extensively for P. falciparum; however, studies on antibody responses to specific P. vivax antigens have been limited to small fragments of the long-standing vaccine candidates merozoite surface protein 1 (PvMSP1) and the circumsporozoite protein (PvCSP). [25] [26] [27] [36] [37] [38] [39] [40] [41] [42] We investigated three communities that have comparable median age but are clearly epidemiologically distinct, differing in time of residence in the endemic area, number of past malaria episodes, and number of patent vivax malaria infections (Table 1) . Male bias in the Colina community may be a confounding variable, especially in regard to analyses with number of past malaria episodes. The effect of gender bias must be considered when interpreting comparative analyses between the communities since men in these communities typically engage in outdoor activities (farming, fishing, logging, etc.) during peak transmission hours and thus have greater overall exposure than women. The communities listed in order of increasing time of residence in the malaria endemic area are 1) Buritis, 2) Colina, and 3) Ribeirinha. Curiously, residents of Ribeirinha reported having the least number of past malaria episodes, despite being natives of the endemic area. This finding is probably a limitation of donorreported data. Most likely, natives underestimate past malaria histories because they do not recall childhood infections. Comparable times since last malaria episode between Colina and Ribeirinha (Table 1 ) not only argues against alternative explanations such as lower malaria transmission or enhanced acquired clinical immunity in the Ribeirinha community, but even suggests that the transmigrant Colina population is acquiring a level of clinical immunity similar to that of the native Ribeirinha population. This is not surprising given that the median number of years of residence in the endemic re- Prevalence refers to the percentage of responders determined as positive for a particular subclass based on optical densities (OD) from subclass-specific enzyme-linked immunosorbent assays. Responders are donors previously determined as having a positive total immunoglobulin G (IgG) response to the indicated antigen. Controls are non-malaria-exposed donors. OD values were converted to g/mL using standard curves for each IgG subclass (see "Materials and Methods" for details). Log or reciprocal transformations were performed as appropriate to normalize the distribution of data points before parametric statistical analyses. Back-transformed 95% confidence intervals of means in g/ml are shown. † Student's t test was used to compare differences between responders and controls within each IgG subclass for a single antigen. Bold typeface indicates the statistically greater of the two groups.
‡ For each antigen, differences in proportions of subclass-specific positive responders (subclass-specific seroprevalence) were compared by 2 test. One-way analysis of variance was used to compare differences between IgG subclass levels within responders or within controls for each antigen. Statistical significance was set at P ‫ס‬ 0.05. NS, not statistically significant. gion for the Colina population approaches that of Ribeirinha. The community of recent transmigrants (Buritis) has the lowest seroprevalence of antibodies against all of the antigens tested when compared with the established communities of Colina and Ribeirinha. Although no significant relationships were found between infection status and seropositivity for any of the antigens (data not shown), the higher frequency of patent P. vivax infections, relative absence of asymptomatic infections, and lowered P. vivax antibody responses observed in the Buritis residents may be indicative of their nonimmune status.
It has long been known that acquired clinical immunity to falciparum malaria depends on repeated exposure to the parasite, a conclusion based on the observation that effective natural immunity to P. falciparum is restricted to areas of high level transmission. 43 The presence of asymptomatic cases in Amazonian communities with long-term malaria exposure reported here and elsewhere suggests that a parallel phenomenon occurs in areas of low P. vivax transmission. 44, 45 This is further supported by our finding that the time that has passed since a donor's last malaria episode positively correlates with the time the donor has resided in the endemic area. The biological basis for such clinical immunity has yet to be elucidated, but it is likely that the effect is partially mediated by antibodies against P. vivax blood stage antigens. We demonstrate that IgG antibody responses to PvDBP and PvRBP1 are dependent on indices of malaria exposure such as time of residence in the endemic area and number of past malaria episodes. Our results coincide with other studies investigating the antibody responses to malaria antigens in areas of low transmission, supporting the view that natural immunologic boosting occurs even with less frequent transmission patterns. 25, 30, 46 Studies on nonimmune transmigrants to hyperendemic areas of Indonesia suggest that immunity to falciparum malaria is age-dependent and that adults acquire protective immunity to chronic infection more rapidly than children. 47 We were not able to investigate whether the clinical immunity we observed was age-dependent as our study was limited primarily to adults. However, incidental crossreactivity of malaria-naïve plasma with Plasmodium antigens, a major component of the age-dependent hypothesis, is suggested in our study by 1) high OD values among a few nonexposed North American and Brazilian controls for several of the antigens tested, resulting in unexpectedly high OD cutoffs and 2) the high frequency of seropositivity (67%) among exposed donors who reported themselves as malaria-naïve. An alternative explanation for seropositivity in this latter group may be unrecalled or subclinical P. vivax infections, as mentioned previously.
Studies on IgG responses against P. falciparum antigens have consistently shown that cytophilic subclasses IgG1 and IgG3 play an important role in a protective antibody response in humans. 22, [48] [49] [50] [51] The proposed mechanism involves parasitic inhibition effected by engagement of Plasmodium-specific cytophilic Ig antibodies to Fc␥ receptors on the surface of monocytes. 23, 24, 52 To date, however, only a small number of studies have investigated cytophilic antibody responses against P. vivax. 53, 54 Although we demonstrate a general predominance of cytophilic IgG antibodies, the correlation to clinical immunity is rather tenuous. The cross-sectional design of this study limited our investigation to retrospective malaria histories, and the best approximation of an individual's protection was the estimated amount of time that had passed since their last malaria episode, a measurement that may be confounded by low or absent exposure to the parasite. We were only able to observe modest, positive correlations between subclass reactivities against the PvRBP1 733-1407 and PvRBP1 1392-2076 antigens and the amount of time since the last infection, only one of which involved a cytophilic subclass. Prospective studies on humoral immune responses or biologic studies addressing the ability of P. vivax antibodies to inhibit merozoite invasion or development will provide more direct evidence with regards to their protective efficacy.
This study attempts to determine the target of antibody responses to PvRBP1 by screening for IgG antibodies to recombinant fragments spanning the extracellular region of the protein. The prevalence of IgG responses to individual PvRBP1 antigens and PvDBP-RII approached 50% and 70%, respectively, comparable to levels previously observed for the PvCSP repeat region and the N-terminal region of PvMSP1. 36, 39 Our results highlight PvRBP1 431-748 and PvRBP1 733-1407 as targets of a natural antibody response, as these regions demonstrate both broad and high-titer responses. Although responses to PvRBP1 733-1407 were more prevalent than those to PvRBP1 431-748 , the latter antigen spans only 318 amino acids of the 2749 residues comprising the PvRBP1 extracellular domain (compared with 675 amino acids for PvRBP1 ). Furthermore, of the 25 total polymorphic residues in PvRBP1, 12 (48%) reside in the region spanned by PvRBP1 . 20 These data taken together suggest that PvRBP1 431-748 may be under immunologic selection pressure. Finer mapping studies are needed to further define the B cell epitopes contained within this region.
The leading strategy for malaria vaccine design calls for a multiple target approach against several blood-stage antigens. 55 Direct comparisons of the natural antibody response to these antigens provide valuable insight as to how such a vaccine might work. We have compared the antibody responses for two promising P. vivax blood-stage targets, PvRBP1 and PvDBP. In addition to the differences in subclass distribution, we show that their IgG responses differ in two important characteristics. First, anti-PvDBP-RII IgG responses appear more prevalent and of higher magnitude than anti-PvRBP1 responses. Second, the rate of IgG antibody acquisition differs between the two antigens. Individuals seem to require less exposure to build up detectable levels of antibodies to PvDBP-RII compared with PvRBP1, implying immunodominance of PvDBP-RII over PvRBP1; the lone exception is the response against PvRBP1 2038-2611 , which shows a rate of increase similar to that of the anti-PvDBP-RII response, albeit at lower prevalence and magnitude. We quantified the rapid acquisition of anti-PvDBP-RII antibodies by logistic regression, showing that donors with more than five malaria episodes were more than five times as likely to respond to this antigen compared with malaria-naïve individuals (Table 4) . However, the regression also suggests that the anti-PvDBP-RII response may be short-lived. Donors who have not had a recent malaria infection (within two months preceding sample collection) were significantly less likely to respond to PvDBP-RII than their recently infected counterparts. In contrast, with the exception of PvRBP1 2038-2611 , the prevalence of responses to PvRBP1 antigens was independent of time since the last known malaria episode. The evidence implies that although anti-PvRBP1 IgG responses may be slowly acquired relative to anti-PvDBP-RII responses, the longevity of such responses may be greater in the absence of clinical malaria episodes.
In conclusion, we have characterized the IgG antibody responses to five distinct regions spanning the extracellular domain of PvRBP1. We show that both PvRBP1 with PvDBP-RII elicit predominantly cytophilic IgG responses but these responses differ in magnitude, breadth, and rate of acquisition, with PvDBP-RII eliciting the more robust and rapid antibody response in three communities of the Brazilian Amazon. These data provide information on the characteristics of acquired humoral immunity to two key vivax antigens in populations exposed to malaria transmission that could be beneficial in the development of a multitarget, blood-stage vaccine for P. vivax. Prospective studies are needed to determine whether synergistic, additive, or antagonistic interactions exist between IgG antibody responses to PvDBP-RII and PvRBP1 as well as their roles in clinical immunity. SUPPLEMENTAL FIGURE 2. Immunoglobulin G subclass calibration curves. Ninety-six well plates were coated with serial dilutions of purified human IgG1, IgG2, IgG3, and IgG4 myeloma proteins (The Binding Site, San Diego, CA). Enzyme-linked immunosorbent assay was performed with the corresponding anti-IgG subcalss monoclonal antibody (Sigma, St. Louis, MO) as described in "Materials and Methods." Points represent experimental data points. Lines correspond to sigmoidal curves representing the best-fit equation for each subclass.
